Treating glioblastoma multiforme with selective high-dose liposomal doxorubicin chemotherapy induced by repeated focused ultrasound

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 965-974

  Yang, Feng Yi ^a   Teng, Ming Che ^a   Lu, Maggie ^b   Liang, Hsiang Fa ^b   Lee, Yan Ru ^a   Yen, Chueh Chuan ^a   Liang, Muh Lii ^a,c   Wong, Tai Tong ^c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Blood brain barrier; Brain tumor; Interleukin 4 receptor; Repeated focused ultrasound; Target drug delivery

Indexed keywords

ANTINEOPLASTIC AGENT; ATHEROSCLEROTIC PLAQUE SPECIFIC PEPTIDE 1 LIPOSOMAL DOXORUBICIN CONJUGATE; DOXORUBICIN; LIPOSOME; UNCLASSIFIED DRUG; INTERLEUKIN 4 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; GLIOBLASTOMA; HIGH INTENSITY FOCUSED ULTRASOUND; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ANIMAL; BLOOD BRAIN BARRIER; BRAIN TUMOR; CYTOCHEMISTRY; DRUG SCREENING; ECHOGRAPHY; FLOW CYTOMETRY; LUMINESCENCE; METABOLISM; METHODOLOGY; MOUSE MUTANT; MULTIMODALITY CANCER THERAPY; PATHOLOGY; ULTRASOUND; ULTRASOUND THERAPY;

ANIMALIA; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DOXORUBICIN; FLOW CYTOMETRY; GLIOBLASTOMA; HISTOCYTOCHEMISTRY; HUMANS; LIPOSOMES; LUMINESCENT MEASUREMENTS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, SCID; RECEPTORS, INTERLEUKIN-4; SONICATION; ULTRASONIC THERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862305857     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S29229     Document Type: Article

References (30)

1. Deen DF, Chiarodo A, Grimm EA, et al. Brain tumor working group report on the 9th international conference on brain tumor research and therapy. Organ System Program, National Cancer Institute. J Neurooncol. 1993;16:243-272.
2. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 1989;86:695-698.
3. Motzer RJ, Mazumdar M, Gulati SC, et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst. 1993;85:1828-1835.
4. Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol. 1997;15:2546-2552.
5. Puri RK, Leland P, Kreitman RJ, Pastan I. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-pseudomonas exotoxin chimeric protein. Int J Cancer. 1994;58:574-581.
6. Joshi BH, Leland P, Asher A, Prayson RA, Varricchio F, Puri RK. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures. Cancer Res. 2001;61:8058-8061.
7. Husain SR, Behari N, Kreitman RJ, Pastan I, Puri RK. Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy. Cancer Res. 1998;58:3649-3653.
8. Hong HY, Lee HY, Kwak W, et al. Phage display selection of peptides that home to atherosclerotic plaques: Il-4 receptor as a candidate target in atherosclerosis. J Cell Mol Med. 2008;12:2003-2014.
9. Yang FY, Wang HE, Lin GL, et al. Micro-SPECT/CT-based pharmacokinetic analysis of 99 mtc-diethylenetriaminepentaacetic acid in rats with blood-brain barrier disruption induced by focused ultrasound. J Nucl Med. 2011;52:478-484.
10. Yang FY, Horng SC, Lin YS, Kao YH. Association between contrastenhanced MR images and blood-brain barrier disruption following transcranial focused ultrasound. J Magn Reson Imaging. 2010;32: 593-599.
11. Yang FY, Lin YS, Kang KH, Chao TK. Reversible blood-brain barrier disruption by repeated transcranial focused ultrasound allows enhanced extravasation. J Control Release. 2011;150:111-116.
12. Yang FY, Liu SH, Ho FM, Chang CH. Effect of ultrasound contrast agent dose on the duration of focused-ultrasound-induced blood-brain barrier disruption. J Acoust Soc Am. 2009;126:3344-3349.
13. Treat LH, McDannold N, Vykhodtseva N, Zhang Y, Tam K, Hynynen K. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer. 2007;121:901-907.
14. Walter KA, Tamargo RJ, Olivi A, Burger PC, Brem H. Intratumoral chemotherapy. Neurosurgery. 1995;37:1128-1145.
15. Cummings J, McArdle CS. Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug. Br J Cancer. 1986;53:835-838.
16. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol. 2005;23:7685-7696.
17. Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. Science. 2004;303:1818-1822.
18. Madhankumar AB, Slagle-Webb B, Wang X, et al. Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. Mol Cancer Ther. 2009;8:648-654.
19. Madhankumar AB, Slagle-Webb B, Mintz A, Sheehan JM, Connor JR. Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. Mol Cancer Ther. 2006;5:3162-3169.
20. Kim JH, Bae SM, Na MH, et al. Facilitated intracellular delivery of peptide-guided nanoparticles in tumor tissues. J Control Release. September 16, 2011. [Epub ahead of print.]
21. Wu XL, Kim JH, Koo H, et al. Tumor-targeting peptide conjugated pH-responsive micelles as a potential drug carrier for cancer therapy. Bioconjug Chem. 2010;21:208-213.
22. Yang FY, Lin GL, Horng SC, et al. Pulsed high-intensity focused ultrasound enhances the relative permeability of the blood-tumor barrier in a glioma-bearing rat model. IEEE Trans Ultrason Ferroelectr Freq Control. 2011;58:964-970.
23. Bachur NR, Moore AL, Bernstein JG, Liu A. Tissue distribution and disposition of daunomycin (ncs-82151) in mice: Fluorometric and isotopic methods. Cancer Chemother Rep. 1970;54:89-94.
24. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res. 2005;11:8782-8788.
25. Lankelma J, Dekker H, Luque FR, et al. Doxorubicin gradients in human breast cancer. Clin Cancer Res. 1999;5:1703-1707.
26. Sharma US, Sharma A, Chau RI, Straubinger RM. Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharm Res. 1997; 14:992-998.
27. Frenkel V, Etherington A, Greene M, et al. Delivery of liposomal doxorubicin (Doxil) in a breast cancer tumor model: Investigation of potential enhancement by pulsed-high intensity focused ultrasound exposure. Acad Radiol. 2006;13:469-479.
28. Bekeredjian R, Chen S, Frenkel PA, Grayburn PA, Shohet RV. Ultrasound-targeted microbubble destruction can repeatedly direct highly specific plasmid expression to the heart. Circulation. 2003;108: 1022-1026.
29. Khaibullina A, Jang BS, Sun H, et al. Pulsed high-intensity focused ultrasound enhances uptake of radiolabeled monoclonal antibody to human epidermoid tumor in nude mice. J Nucl Med. 2008;49:295-302.
30. Kollmannsberger C, Nichols C, Bamberg M, et al. First-line high-dose chemotherapy c///radiation therapy in patients with metastatic germ-cell cancer and brain metastases. Ann Oncol. 2000;11:553-559.